Immunovant replaces CEO, makes other changes as Roivant tightens control

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Immunovant on Monday announced changes to its management team, including the naming of a new chief executive, intended to give its majority owner, Roivant Sciences, greater control over the biotech company’s operations.

Pete Salzmann, Immunovant’s current CEO and board member, is retiring. He will be replaced by Eric Venker, Roivant’s current president and chief operating officer. Immunovant CFO Renee Barnett is also leaving, to be replaced by Tiago Girao, currently the CFO of Televant, another Roivant affiliate company. 

Immunovant was spun out of Roivant in 2019 to develop a pipeline of drugs to treat autoimmune disorders. While Immunovant is its own publicly traded entity, Roivant retains 57% ownership, giving it de facto control. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Individual plans

Group plans

View All Plans